Abstract

ADALIMUMAB (HUMIRA): A MILESTONE IN THE MANAGEMENT OF NON-INFECTIOUS UVEITIS

Waris A., Ansari N. N.* and Akhtar N.

ABSTRACT

Adalimumab (Humira, AbbVie) is a fully human monoclonal immunoglobulin G 1 (IgG1) tumor necrosis factor alpha (TNF-α) antibody. It received regulatory approval from the US Food and Drug Administration (FDA) in June for the treatment of noninfectious intermediate, posterior, and panuveitis in adults. Before this, adalimumab had FDA approval for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis (JIA), psoriatic arthritis, ankylosing spondylitis (AS), and Crohn disease.[1] In recent evidence-based interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with JIA, adalimumab is recommended as the preferred TNF-αinhibitor.[2]

Keywords: Adalimumab (Humira), non-infectious uveitis, FDA approval.